Brief: Lumos Pharma Reports Q3 loss Of $0.86 Per Share

Lumos Pharma

14/11/2022 11:20

Nov 14 (Reuters) - Lumos Pharma Inc  LUMO.O :
    * LUMOS PHARMA REPORTS THIRD QUARTER 2022 FINANCIAL RESULTS
AND
CLINICAL DEVELOPMENT UPDATES
    * ENDED QUARTER ON SEPTEMBER 30, 2022 WITH CASH AND CASH
EQUIVALENTS TOTALING $73.7 MILLION
    * QTRLY LOSS PER SHARE $0.86
    * Q3 EARNINGS PER SHARE VIEW $-1.01 -- REFINITIV IBES DATA
    * QTRLY REVENUE $497 MILLION
    * Q3 REVENUE VIEW $66670.00 -- REFINITIV IBES DATA
    * ORAGROWTH210 TRIAL IS 80% ENROLLED AND PRIMARY OUTCOME
READOUT
WITH ALL 80 SUBJECTS AT SIX MONTHS ANTICIPATED 2H 2023
    * LUMOS PHARMA - INTERIM DATA FOR POTENTIALLY FIRST ORAL
MEDICATION FOR PGHD FROM PHASE 2 ORAGROWTH210 AND PK/PD
ORAGROWTH212 TRIALS MET EXPECTATIONS
    * CASH OF $73.7 MILLION AT END OF Q3 2022 PROVIDES RUNWAY
INTO Q2
2024

Source text for Eikon:  ID:nGNX5lctcY 
Further company coverage:  LUMO.O 
 ((Reuters.Briefs@thomsonreuters.com;))